Silencing of individual genes can occur by genetic and epigenetic processes during carcinogenesis, but the underlying mechanisms remain unclear. By creating an integrated prostate cancer epigenome map using tiling arrays, we show that contiguous regions of gene suppression commonly occur through long-range epigenetic silencing (LRES). We identified 47 LRES regions in prostate cancer, typically spanning about 2 Mb and harbouring approximately 12 genes, with a prevalence of tumour suppressor and miRNA genes. Our data reveal that LRES is associated with regional histone deacetylation combined with subdomains of different epigenetic remodelling patterns, which include re-enforcement, gain or exchange of repressive histone, and DNA methylation marks. The transcriptional and epigenetic state of genes in normal prostate epithelial and human embryonic stem cells can play a critical part in defining the mode of cancer-associated epigenetic remodelling. We propose that consolidation or effective reduction of the cancer genome commonly occurs in domains through a combination of LRES and LOH or genomic deletion, resulting in reduced transcriptional plasticity within these regions.
1
. DNA hypermethylation of CpG islands is a widespread feature of cancer cells, is associated with transcriptional repression, and is functionally equivalent to physical deletion of the gene 2 . Chromatin structure also determines the functional state of a gene 3 , and modifications to histone tails are commonly deregulated in cancer 4 . Polycomb group proteins are histone-associated proteins that have a role in gene silencing during development 5 and in epigenetic silencing in cancer [6] [7] [8] [9] [10] [11] . CpG island-associated genes associated with pluripotency of embryonic stem (hES) and progenitor cells are often marked by histone H3 Lys 27 trimethylation (H3K27me3) polycomb marks 12 . Intriguingly, it is these polycomb target genes that constitute a significant fraction of genes that are hypermethylated in cancer cells 8, 9, 11 , suggesting that H3K27me3 may trigger aberrant DNA methylation by recruitment of DNA methylation machinery.
A driving force underpinning much recent work in cancer epigenetics has been the quest to identify genes that are methylated in cancer, to provide biomarkers for cancer detection or prognosis. Previous studies using candidate gene approaches or global array surveys have found that hundreds of discrete CpG island-associated genes can be differentially methylated in cancer. Previously, we identified a 4-Mb region on chromosome 2q14.2 in colorectal cancer, where DNA hypermethylation was not restricted to discrete CpG islands or single genes, but encompassed multiple adjacent CpG rich regions, with concordant gene silencing 13, 14 . Suppression of neighbouring unmethylated genes was associated with chromatin remodelling in a process we termed long range epigenetic silencing (LRES). Similar concordant methylation of adjacent CpG island gene promoters has also been reported for a number of gene clusters in cancer [15] [16] [17] , including the HOXA gene cluster 18 . Recent genome-scale analyses also identified other large chromosomal regions containing several CpG islands often methylated and transcriptionally repressed in cancer 14, [19] [20] [21] , suggesting that coordinate epigenetic control over larger regions may be a common phenomenon.
We have now used an integrated genomics approach to survey the frequency of LRES in prostate cancer and determine the underlying features common to regional epigenetic suppression. We found that on Genes Initially, nine regions (dashed columns) were identified on this chromosome with concordant downregulation in both experimental datasets (Exp1: tumour (T) versus normal (N) 63 ; Exp2: T versus N 64 ). Results were combined with expression studies on 5-Aza-dC (Aza)-treated prostate cancer cell lines 22 to examine potential epigenetic repression. The numbered yellow columns show regions with LRES potential: four or more consecutively repressed genes and no upregulated probe sets in the clinical samples, plus evidence of upregulation after 5-Aza-dC treatment in the cell line samples: region 22 (7p15.2-p15.1) containing the HOXA cluster, region 23 (7q22.1) with several cytochrome P450 (CYP) and zinc finger (ZNF) genes, and region 24 (7q31.1-q31.2) with 11 genes including CAV1 and CAV2. Dashed columns indicated with an asterisk are regions that were discarded from further analysis as they contain less than 4 genes and/or did not show any upregulation in the 5-Aza-dC experiments. (c) Gene suppression at each probe set is shown across the 4.1-Mb region spanning 7q31 for experiments 1 and 2 (T versus N), and metastatic (M) versus normal (N) prostate is shown separately for experiment 2 (Down, downregulated; BD, below detection; NC, not changed; Up, upregulated. Gene suppression at each probe set is also shown for nine large Oncomine studies where local prostate cancer was compared with normal prostate samples. Location of the genes and CpG islands and chromosome coordinates are indicated below for region 24. a local scale, adjacent genes commonly show the same epigenetic silencing state. However in LRES regions epigenetic repression is extended to encompass multiple genes that are characterized by an overall loss of active histone marks and focal replacement and/or re-enforcement of repressive histone and DNA methylation marks. We conclude that the cancer epigenome is commonly deregulated in domains that are associated with an overall reduction in transcriptional plasticity in LRES regions, compared with the bivalent and/or permissive states found in hES and normal prostate epithelial cells.
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RESULTS
LRES is common in clinical prostate cancer
To determine whether LRES occurs commonly in cancer, we sought to identify genomic regions that frequently show concordant gene silencing in prostate cancer, compared with matched normal tissue. First, we re-analysed two publicly available expression datasets for differential gene expression in clinical samples, using a computational sliding window algorithm that identified regions of coordinate downregulation (Fig. 1a) . To identify regions that were potentially epigenetically suppressed, rather than lacking expression because of genomic deletion or LOH, we re-analysed a third dataset consisting of four prostate cancer cell lines (LNCaP, DU145, PC3 and MDA-2A) treated with DNA methyltransferase inhibitor 5-Aza-dC 22 (Fig. 1b) . Regions were classified as candidates for LRES if they: 1) contained probe sets detecting four or more consecutive genes that were repressed or silent in prostate cancer samples from two clinical data sets; 2) were essentially devoid of upregulated probe sets; and 3) contained upregulated probe sets in at least two of four prostate cancer cell lines after 5-Aza-dC treatment. Figure 1b summarizes the combined data for chromosome 7, with three putative LRES regions identified (22) (23) (24) ; Supplementary Information, Additional File 1 summarizes the putative LRES regions (1-47) across all chromosomes. Further, gene expression levels from the candidate LRES regions were compared in nine large Oncomine prostate cancer studies [23] [24] [25] [26] [27] [28] [29] [30] [31] , allowing comparison of results from 215 normal prostate and 380 local prostate cancer samples. The Oncomine data for region 24 shows common gene suppression across a 4.1-Mb region, (Figure 1c ; see Supplementary Information, Additional File 2 for a summary of all LRES regions). Putative LRES regions were excluded if no further evidence for regional gene suppression was obtained from these comparative studies.
Using this rigorous integrative approach, we identified 47 candidate LRES regions, with concordant gene suppression in multiple prostate cancer data sets (Table 1; Supplementary Information, Table S1 ). The LRES regions have an average size of 1.9 Mb (range: 0.2-5.1 Mb) and contain on average 12 genes (range: 5-28); 71% have CpG island-associated promoters and in total span 2.9% of the genome. Commonly, the region of suppression is broader in metastatic than localized cancer, indicating a potential spreading of LRES during progression. For example, in chromosome 1, regions 1-7 show increased regional repression in the metastatic samples (Exp2), and LRES regions 2-3 seem to converge (Supplementary Information, Additional File 1). Chromosomes with high LRES coverage are 18, 6 and X (7.5, 5.6 and 5.5%, respectively), whereas the smallest chromosomes (19, 20, 21 and Y), chromosomes 13 and 14, and centromeric and telomeric areas are devoid of any LRES regions by these strict criteria ( Supplementary Information, Fig. S1 ). LRES regions predominate in the lighter cytogenetic G-bands, with 79% of LRES regions overlapping the lighter stained Giemsa regions that comprise 68% of the genome ( Supplementary Information, Fig. S1 ). However, minimal enrichment of gene or CpG density in LRES regions relative to the entire genome was found. Additionally, there was little difference in the abundance of DNA repeat elements (LINE, SINE, LTR), or enrichment of predicted methylation-prone/resistant motifs 32 , lamina-associated domains 33 or highly conserved non-coding elements 34 Supplementary Information, Fig. S2 . To ensure that gene repression in LNCaP was not caused solely by chromosomal deletions, we overlaid copy number variation (CNV) data from LNCaP cells and found 30/35 showed no evidence of deletion, whereas five LRES regions showed loss of one allele (Supplementary Information, Table S1 ).
For expression array validation, we performed qRT-PCR for genes within, and flanking LRES region 24 (7q31.1-q31.2; Fig. 3a, c) (Fig. 3a-c) . ASZ1 was methylated in PrEC, whereas WNT2, CFTR and CTTNBP2 were unmethylated. In LNCaP, the entire block was extensively methylated ( 
LRES in clinical prostate cancers
To confirm whether the epigenetic states observed in LNCaP cells also occur in clinical samples, we examined expression and DNA methylation of genes spanning region 24 (7q31.1-q31.2) in DNA from five local prostate cancer and matched normal samples. Analysis of individual patient samples confirms that regional gene expression is decreased (Fig. 4a) . DNA methylation levels were also similar to the LNCaP data with MDFIC and TES, showing minimal DNA methylation in the clinical samples, whereas CAV1, CAV2, and CFTR showed significant DNA hypermethylation (Fig. 4b) . For WNT2, CAV1 and CAV2 clonal bisulphite sequencing analysis revealed that approximately half the molecules were methylated at some sites (patients 16 and 29), consistent with allele-specific methylation of the region (Fig. 4c ), or contamination with normal cells. These results provide supporting evidence that LRES regions are also susceptible to DNA methylation in clinical prostate cancer.
Overview of cancer-associated epigenetic changes in LRES regions
Gene expression, histone modification and DNA methylation were analysed collectively for the 376 gene promoters in the 35 common LRES regions in LNCaP cells. LRES-associated genes consistently showed lower RNA and H3K9ac signals in LNCaP, compared with PrEC cells (Wilcoxon rank sum test; P <0.0001; Fig. 5a ). The repressive mark H3K9me2 showed only modest differences, whereas changes in H3K27me3 and DNA methylation were more pronounced and varied, with most genes showing a stronger signal for H3K27me3 and DNA methylation in LNCaP, compared with PrEC (P <0.0005; Fig. 5a ). A positive correlation between RNA and H3K9ac levels was detected in both PrEC and LNCaP cells ( Fig. 5b ; Supplementary Information, Table S4 ). H3K9ac and H3K9me2 signals were mutually exclusive, as were H3K9ac and H3K27me3 signals. A similar negative association was found between RNA, H3K9me2 and H3K27me3 (Supplementary Information, Table S4 ). DNA methylation was low in genes with high H3K9ac signals, whereas a lack of H3K9ac was associated with either a hypo-or hyper-state of DNA methylation. H3K9me2 and H3K27me3 signals can be found on the same genes (positive correlation), whereas DNA methylation seems to be absent when H3K27me3 is high, especially in LNCaP cells, (Supplementary Information, Table S4 ). When comparing differences in marks between PrEC and LNCaP ( Supplementary Information, Fig. S4 ), we noted that lower RNA levels were associated with depletion in H3K9ac, whereas repressive marks H3K9me2, H3K27me3 and DNA methylation levels were generally higher. To our surprise, no clear correlations were observed in LRES regions between changes in H3K9me2, H3K27me3 and DNA methylation, indicating that, in addition to global deacetylation, combinations of different epigenetic silencing modes are involved.
Consolidation of the cancer epigenome into domains of repressive chromatin
From the detailed epigenetic analysis, it is evident that LRES-associated changes occur mainly in blocks of multiple consecutive genes ( Fig. 6a-c) .
Common to all LRES regions was an overall loss in H3K9 acetylation that was associated with reduced gene transcription. We also observed that clustering of epigenetic marks occurs frequently in domains (WaldWolfowitz test), but the distribution of subdomains in the LRES regions vary in the combination of repressive marks. For example, region 24 contains a large repressed domain, with depletion in H3K9 acetylation and a gain of H3K27me3 (Fig. 6a) . A second repressed domain, 
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Prostate cancer-associated LRES regions are in permissive chromatin domains in hES cells
There is increasing evidence, as well as some debate 35, 36 , that cancer cells possess many characteristics ascribed to normal undifferentiated (pluripotent) stem cells, possibly reflecting the origin of cancer in tissue stem cells or de-differentiation and activation of stem cell-like gene expression patterns in cancer development. Because the cells of origin of human prostate cancer are poorly understood, we examined whether LRES regions resembled more the epigenetic state of pluripotent hES cells than PrEC cells. Analysis in hES cells reveals that many LRES genes are not expressed or expressed at low levels in both LNCaP and hES cells relative to PrEC cells ( Supplementary  Information, Fig. S5 ). However the active H3K9ac mark is notably depleted in the LRES regions of LNCaP relative to hES and PrEC cells ( Supplementary  Information, Fig S5) . Moreover, H3K4me3 is also generally depleted in LRES regions of LNCaP, compared with PrEC, and more distinctly depleted relative to hES cells. Interestingly, there is also a clear loss of H3K4me3 in PrEC cells relative to hES cells. In comparison, levels of the repressive polycomb H3K27me3 signal are more widely scattered between all three cell types (see Supplementary Information, Additional File 4 for more details). These results indicate that there is not an overall trend for LRES regions to revert to a chromatin state similar to that of pluripotent hES cells, but supports the concept of epigenome remodelling from permissive and/or bivalent states during differentiation, with a progressive acquisition of repressive histone marks across domains during tumorigenesis.
Clustering of epigenetic change in adjacent genes
To address whether regional epigenetic suppressive marks were restricted to LRES regions, we calculated the frequency at which adjacent genes showed a significant epigenetic change in the same direction, comparing PrEC and LNCaP cells. For all epigenetic marks, the observed number of changes was significantly greater than expected (P <1 × 10 -9 at the transcription start site; Fig. 6d ). The strongest evidence for clustering of Statistical analysis of the number of adjacent gene pairs in the genome that show the same epigenetic change revealed that clustering occurs much more frequently than by chance (***P <1 × 10 -09 or 10 -10 log 10 ; P >9). Clustering occurs for all epigenetic marks interrogated and in both directions implicating a deregulation of the cancer epigenome into domains that include multiple genes (upregulation: left graph; downregulation: middle graph; log transformed P values for changes: right graph).
nature cell biology VOLUME 12 | NUMBER 3 | MARCH 2010 2 4 3 epigenetic changes in adjacent genes was found for the increase in H3K27 methylation. Interestingly, in hES cells we also found that adjacent genes had a greater probability (P <1 × 10 -22 , Kolmogorov-Smirnov test) of harbouring the same epigenetic (H3K9ac, H3K4me3 and H3K27me3) mark ( Supplementary Information, Fig. S6 ). These data further support the observation that, on a local scale, adjacent genes are more likely to follow the same epigenetic change during tumourigenesis, as we observed in LRES regions.
DISCUSSION
This study is one of the first to investigate and integrate multi-study clinical prostate cancer expression data with complex multilayered epigenome data. We have built a comprehensive prostate cancer epigenome map to answer important questions on the prevalence and mode of action of LRES in prostate cancer. Our data reveal that LRES is a common event in prostate cancer and affects a significant proportion of the cancer genome.
One of the main features common to LRES genomic locations is the overlap with regions of genomic deletion or LOH, reported in prostate and other cancers [37] [38] [39] . It is widely accepted that genetic and/or epigenetic processes can silence single genes involved in tumorigenesis. We now propose that LOH and LRES, acting either independently or simultaneously on different alleles, can also result in regional gene suppression in cancer. The common overlap of LOH/genomic deletion and LRES regions may reflect the presence of genes that play a part in cancer, with loss of expression providing a growth advantage. Indeed, more than a third of LRES regions harbour known tumour-suppressor, tumour-related 13, [39] [40] [41] [42] [43] [44] [45] [46] and miRNA genes [47] [48] [49] [50] [51] . A mechanistic relationship connecting genomic deletion and/or LOH to LRES is not clear. There may be underlying chromosomal features that predispose these genomic regions to either regional epigenetic silencing or deletion, or epigenetic silencing may itself predispose a region to subsequent deletion. It has been suggested that double-strand breaks and DNA repair may lead to epigenetic remodelling and histone modification 52, 53 or, conversely, that compromised chromatin is less efficient for DNA double-strand break repair and prone to chromosomal aberration 54 . In addition to genomic features, we investigated epigenomic features associated with LRES regions in prostate cancer cells. The overriding feature was an overall depletion of H3K9 acetylation that occurred, not only in neighbouring genes that were active in normal prostate, but also in genes that were silent in normal prostate or hES cells. In addition to global deacetylation, we were surprised to find distinct combinations of epigenetic silencing marks, spanning multiple genes in domains in each of the LRES regions. Three main types of epigenetically distinct cancer-associated domains were found (Fig. 7) . First, 're-enforcement' of repressive marks to a more definitively repressed state; re-enforcement occurs in regions that are predominately suppressed in normal prostate and hES cells, and are marked by even lower levels of H3K9ac, an enrichment of H3K9me2 and higher H3K27me3 levels, and in some cases localized DNA hypermethylation. Second, 'gain' of multiple repressive marks in regions that were clearly active and associated with H3K9 hyperacetylation in normal prostate and hES cells; these repressive marks include a complete lack of H3K9ac and presence of H3K27me3 and also can include elevated H3K9me2 and DNA hypermethylation. Third, 'exchange' of repressive marks is seen in genes that are inactive or expressed at low levels in normal prostate and hES cells; exchange commonly involves a lack of the H3K27me3 mark and higher DNA methylation, especially in genes normally bearing bivalent marks in hES cells, or a combination of active (H3K9ac) and repressive (H3K27me3) marks in PrEC cells. In some cases however, especially in non CpG island-associated genes, a lack of DNA methylation and elevated H3K27me3 and H3K9me2 marks is observed. The transcriptional state of the gene in the normal cell commonly predicts the mode of epigenetic remodelling observed Cancer cells
Figure 7
Consolidation of the cancer epigenome into domains of repressive chromatin by LRES. Within LRES regions in cancer, but also throughout the rest of the cancer genome, epigenetic changes frequently occur in domains of consecutive genes. Three types of domains can be identified: 1) Repressive marks can be re-enforced to a more definitively repressed state. Complete repression of such a region is frequently marked with a gain of H3K27 trimethylation and sporadic DNA hypermethylation. 2) A gain of (multiple) repressive marks is often observed in regions that were clearly active and associated with H3K9 hyperacetylation in the normal state. 3) An exchange of repressive marks, either from H3K27me3 to DNA methylation or the inverse is seen for regions that display only low expression levels in normal cells.
in the cancer cell. We propose that all three major remodelling patterns that occur in LRES regions contribute to consolidation or reduction of the accessible genome potentially available for any normal transcriptional response in the cancer cell. Across the whole genome we found that for all epigenetic marks, adjacent pairs were more likely to differ concordantly in cancer. This supports the concept that many local chromosomal regions are under coordinated epigenetic control, and that the stringent criteria we have applied to identify LRES regions has selected a subset of a more general phenomenon.
Single genes have been reported recently to undergo different modes of epigenetic reprogramming, most notably 'epigenetic switching' , which occurs in developmental genes that are silent and associated with H3K27me3 in normal cells, but in cancer, these genes are susceptible to DNA methylation and lose the polycomb mark 55 . However, epigenetic switching has not been reported to occur in clusters. Clustering of chromatin marks does occur to some extent in normal cells. For example the organization of the genome into euchromatin and heterochromatin is well established and G and R banding is thought to be associated with enrichment or depletion of repressive histone marks 56 . More recently, two studies described a single epigenetic mark that formed domains in the normal (mouse) genome; H3K9me2 domains (LOCKs) were found to be acquired during normal cell differentiation and were associated with gene silencing over large regions 57 ; domains of H3K27me3 (BLOCs) seemed to span silent genes in normal fibroblasts 58 . Chromatin of undifferentiated hES cells is less condensed and has higher plasticity, compared with that of the differentiated cell [59] [60] [61] [62] . We propose that LRES in cancer results in yet further consolidation of the genome to a more definitive epigenetic repressive state across large domains, affecting a large variety of epigenetic marks, resulting in reduced transcriptional plasticity. Indeed, some LRES regions seem to expand into neighbouring genes in metastatic disease, suggesting a role for LRES in tumour progression, which is potentially seeded by epigenetic silencing of a critical gene or genes involved in cancer initiation. Our study has important implications in development of epigeneticbased cancer treatment strategies that may be required to reactivate genes in chromosomal domains that are overlaid with multiple repressive epigenetic marks. 
METHODS
Methods
METHODS
Cell lines and culture conditions. LNCaP prostate cancer cells were cultured as described previously 65 , and DU145 and PC3 were cultured in RPMI 1640 medium (Gibco) supplemented with fetal calf serum. Two independent cultures of normal prostate epithelial cells (PrEC, catalogue no. CC-2555: PrEC 1 and PrEC 2 ; tissue acquisition numbers 13683 and 13639; Cambrex Bio Science) were cultured according to the manufacturer's instructions in prostate epithelial growth medium (PrEGM, catalogue no. CC-3166; Cambrex Bio Science).
Gene expression array analysis. RNA was extracted from cell lines using Trizol reagent (Invitrogen) according to the manufacturer's protocol, and the integrity confirmed using an Agilent Bioanalyzer. RNA (300 ng) was labelled according to Affymetrix GeneChip whole transcript (WT) sense target labelling assay manual (P/N 701880 Rev. 4) with changes applied as noted in Addendum P/N 702577, Rev. 1. GeneChip human gene 1.0ST arrays (Affymetrix) were used and hybridizations were performed according to the manufacturer's instructions, and array analyses using expression console version 1.1 (Affymetrix) and default parameters. All raw and analysed expression array data has been deposited in NCBI's Gene Expression Omnibus (GEO) under accession no. GSE19726.
Quantitative real-time RT-PCR validation analysis. cDNA was reverse-transcribed with 150 ng of random hexamers (Roche) from 1 μg of total RNA using SuperScript III RNase H-reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Expression was quantified using the ABI PRISM 7900HT sequence detection system, as described previously 66 . The primers used for RT-PCR amplification are listed in Supplementary Information, Table S5 . Reactions were performed in triplicate, and standard deviations calculated using the comparative method (ABI PRISM 7700 sequence detection system, user bulletin no. 2, 1997).
Methylation profiling by MeDIP. The MeDIP assay was performed on 4 μg of sonicated genomic DNA (300-500 bp) in 1 × IP buffer (10 mM sodium phosphate pH 7.0, 140 mM NaCl and 0.05% Triton X-100). Anti-5-methylcytosine mouse monoclonal antibody (10 μg; Calbiochem clone 162 33 D3 catalogue no. NA81) was incubated overnight in 500 μl 1 × IP buffer and the DNA/antibody complexes were collected with 80 μl Protein A/G Plus agarose beads (Santa Cruz sc-2003). The beads were washed three times with 1 × IP buffer at 4°C and twice with 1 ml TE buffer at room temperature. Immune complexes were eluted with freshly prepared 1% SDS, 0.1 M NaHCO 3 , and DNA was purified by phenol/chloroform extraction, ethanol precipitation and resuspended in 30 μl H 2 O. Input samples were processed in parallel.
Chromatin immunoprecipitation (ChIP) assays. ChIP assays were carried out according to the manufacturer's protocol (Upstate Biotechnology). Briefly, about 10 6 cells, in a 10 cm dish, were fixed by adding formaldehyde at a final concentration of 1% and incubating for 10 min at 37°C. The cells were washed twice with ice cold PBS containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride (PMSF), 1 μg ml -1 aprotinin and 1 μg ml -1 pepstatin A), collected and treated with SDS lysis buffer for 10 min on ice. Resulting lysates were sonicated to shear the DNA to fragment lengths of 200-500 bp. Complexes were immunoprecipitated with antibodies specific for acetylated histone H3 Lys 9 (H3K9ac; Millipore no. 06-599), trimethylated histone H3 Lys 4 (H3K4me3; Abcam no. ab8580), dimethyl histone H3 Lys 9 (H3K9me2) (Abcam no. ab1220) and trimethyl histone H3 Lys 27 (H3K27me3; Millipore no. 07-449). A 10-μl aliquot of antibody was used for each immunoprecipitation. No antibody controls were included for each ChIP assay and no precipitation was observed by quantitative real-time qPCR analysis. Input samples were processed in parallel. Antibody-protein complexes were collected by either salmon sperm DNA/protein A agarose slurry or Protein A/G Plus agarose beads (Santa Cruz sc-2003) and washed several times. Immunocomplexes were eluted with 1% SDS and 0.1 M NaHCO 3 and samples treated with proteinase K for 1 h. DNA was purified by phenol/chloroform extraction, ethanol precipitation and resuspended in 30 μl H 2 O.
Whole genome amplification and promoter array analyses. Immunoprecipitated DNA and input DNA from MeDIP and ChIP immunoprecipitations was amplified with GenomePlex complete whole genome amplification (WGA) kit (Sigma catalogue no. WGA2) according to the manufacturer's instructions, using 50 ng of DNA in each amplification reaction. Reactions were cleaned up using cDNA cleanup columns (Affymetrix no. 900371), and 7.5 μg of amplified DNA was fragmented and labelled according to Affymetrix chromatin immunoprecipitation assay protocol P/N 702238 Rev. 3. Affymetrix GeneChip Human Promoter 1.0R arrays (P/N. 900777) were hybridized using the GeneChip hybridization wash and stain kit (P/N 900720). Array analyses for immunoprecipitated signal compared to input were performed using model-based analysis of tiling-arrays (MAT) 67 with a bandwidth of 1 kb, using biological duplicates. Normalization to input signals corrects for copy number changes between the cell lines. All other parameters used within MAT are the defaults. MeDIP of SssI methylated DNA was hybridized in duplicate to the Affymetrix promoter arrays to facilitate interpretation of the MAT scores. Enrichment of MeDIP and ChIP signals between LNCaP and PrEC cells were visualised using Integrated Genome Browser (IGB; Affymetrix). All raw and analysed tiling array data has been deposited in NCBI's Gene Expression Omnibus (GEO) under accession no. GSE19726.
Validation of ChIP-chip arrays by qPCR analysis. Quantitative real-time PCR analysis was performed to validate the ChIP-chip tiling array results. The amount of target immunoprecipitated was measured by qPCR using the ABI Prism 7900HT sequence detection system. Amplification primers used for validation are listed in Supplementary Information, Table S5 . PCR reactions were set up according to the sequence detection system compendium (V 2.1) for the 7900HT Applied Biosystems Sequence Detector. Reactions (10 μl) were performed in triplicate using the Power SYBR Green PCR Master Mix (2x) in a 384-well plate. Immunoprecipitated DNA (3 μl, diluted 1:10), no antibody control or input chromatin were used in each PCR. Universal thermal cycling conditions were used; 50°C for 2 min, then 95°C for 10 min, followed by 95°C for 15 s and 60°C for 1 min, repeated for 40 cycles. For each sample an average C T value was obtained for immunoprecipitated material and for input chromatin. The difference in C T values (δC T ) reflects the difference in the amount of material that was immunoprecipitated relative to the amount of input chromatin (ABI PRISM 7700 sequence detection system User Bulletin no. 2, 1997 (P/N 4303859). Standard deviation was calculated using the comparative method (ABI PRISM 7700 sequence detection system User Bulletin no. 2, 1997 (P/N 4303859).
DNA methylation analysis using bisulphite sequencing and Sequenom analysis. DNA was extracted from cell lines using the Puragene extraction kit (Gentra Systems). DNA from tumour and normal prostate samples 68 was prepared with DNeasy blood and tissue kit (Qiagen). Bisulphite treatment was carried out using the EZ-96 DNA methylation-gold kit (catalogue no.D5008; Zymo Research) according to the manufacturer's instructions (18 μl was used in the bisulphite reaction containing 180 ng DNA). The bisulphite-treated DNA was resuspended in 50 μl, and 2 μl was used in each PCR. Cell line DNA was bisulphite-treated as described previously 69 . Following bisulphite conversion, DNA was amplified by PCR in triplicate using primers listed in Supplementary Information, Table S5 . Sequenom methylation analysis was performed as described previously 70 . For clonal analysis, three independent PCR reactions were performed and products pooled to ensure a representative methylation profile. PCR products were purified using the Wizard PCR DNA purification system and cloned into the pGEM-TEasy Vector (Promega) using the Rapid Ligation Buffer System (Promega). Individual clones were purified and sequenced and the methylation status for each CpG site was determined.
Gene expression computational analysis. Sliding window algorithm (SWA): A computational approach was developed to survey the entire genome for regions of coordinate downregulation and low expression (that is, candidate regions LRES) where a 500-kb nucleotide sliding window moved along the genome in increments of 1,000 nucleotides, recording the number and proportion of downregulated and low expression probes within a 500-kb region (script available on request). Every window was ranked according to its proportional score and compared with genes upregulated after 5-Aza-dC. Because each window has corresponding chromosomal coordinates, the best scoring windows point directly to 500-kb regions of potential epigenetic suppression in cancer tissue. We applied the SWA to three publicly available data sets run on whole genome Affymetrix arrays (HG-U133A/B & HG-U133plus2). Exp1: 26 arrays (13 matched normal/ tumour Gleason score 6-8) (ArrayExpress E-TABM-26) 68 . Exp2: A second dataset from the Gene Expression Omnibus (GE3325) consisted of six benign prostate 
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Figure S6 Clustering analysis of chromatin marks in hES cells.
To examine the prevalence of epigenetic marks in hES cells, we ranked gene promoter ChIP-seq counts for H3K9ac, H3K27me3 and H3K4me3. Promoters with above 75 th percentile of each individual modifications number of counts were deemed to be positively marked, and the genome assessed for the presence of consecutive runs of marked genes. The frequency and length of runs of consecutive promoters marked with each of the modifications is significantly greater than expected by chance (p < 1x10 -22 , Kolmogorov-Smirnov test, random distribution determined by 100 permutations). Coolen_Supplementary_Information_Figure_S6
